Wei Wei, Xu Rubin, Ying Xiaomei, Chen Liang, Lu Xiaohuan, Tang Qikai, Xie Jiaheng, Yu Hongzhu
Department of General Surgery, Fuyang Hospital of Anhui Medical University, Fuyang, China.
Department of General Surgery, Suzhou Hospital of Anhui Medical University, Suzhou, China.
Front Genet. 2022 Mar 23;13:856393. doi: 10.3389/fgene.2022.856393. eCollection 2022.
Hepatocellular carcinoma (HCC) is one of the most common types of cancer, and its treatment remains difficult. Since the early symptoms of HCC are not obvious, many HCC patients are already at an advanced stage of the disease at the time of diagnosis. Although current targeted therapy and immunotherapy have been initially effective in HCC patients, several patients have shown low response rates or developed drug resistance, which leads to tumor progression and even death. Hence, there is an urgent need for new biomarkers to guide the prognosis and treatment of HCC. In our study, a prognostic signature consisting of nine SLC genes was constructed in HCC by comprehensive analysis. By calculating risk scores, HCC patients could be divided into high-risk and low-risk groups, with the high-risk group having a significantly poorer prognosis. In addition, we found a hub gene, SLC7A11, which is a robust prognostic marker of HCC. In conclusion, our study can serve as a reference for the prognostic evaluation and treatment of HCC.
肝细胞癌（HCC）是最常见的癌症类型之一，其治疗仍然困难。由于HCC的早期症状不明显，许多HCC患者在诊断时已处于疾病晚期。尽管目前的靶向治疗和免疫治疗在HCC患者中最初已显示出疗效，但一些患者显示出低反应率或产生耐药性，这导致肿瘤进展甚至死亡。因此，迫切需要新的生物标志物来指导HCC的预后和治疗。在我们的研究中，通过综合分析在HCC中构建了一个由九个溶质载体（SLC）基因组成的预后特征。通过计算风险评分，HCC患者可分为高风险组和低风险组，高风险组的预后明显较差。此外，我们发现了一个核心基因SLC7A11，它是HCC的一个强大的预后标志物。总之，我们的研究可为HCC的预后评估和治疗提供参考。
